Abbott completes AMO acquisition

Article

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Abbott Laboratories has completed its acquisition of Advanced Medical Optics (AMO), paying $1.24 billion for 83% of the fully-diluted stock and assuming around $1.4 billion of AMO's long-term debt.

Scott Stoffel, director of financial and litigation communications at Abbott remarked, "Our four major business divisions all delivered double-digit percentages of growth during the past year, resulting in 14% growth of our full-year 2008 sales. This leaves us in a very confident position for purchasing AMO, which is a global leader in eye-care devices."

As a subsidiary of Abbott, AMO will now be known as Abbott Medical Optics. The sales representatives, customer service team and pricing and ordering structure will remain the same.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.